M
Milestone Pharmaceuticals Inc. (MIST)
NMS – Real Time Price. Currency in USD
1.04
-0.11 (-9.57%)
At close: Mar 27, 2026, 4:00 PM EDT
1.04
0.00 (0.00%)
After-hours: Mar 27, 2026, 7:51 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
1.04
-0.11 (-9.57%)
At close: Mar 27, 2026, 4:00 PM EDT
1.04
0.00 (0.00%)
After-hours: Mar 27, 2026, 7:51 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.01 | 6.05 | 10 | |
| Quick ratio | 7.96 | 5.63 | 10 | |
| Debt to Equity | 1.40 | 0.30 | 5.0 | |
| Debt to Assets | 0.51 | 1.04 | 4.0 | |
| Interest coverage | -17.62 | -16.91 | 1.0 | |
| Weighted average score | 6.0 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 5M | 1M | N/A | 2M | 2M |
| Gross Profit | 5M | 402K | -646K | 1M | 1M |
| Operating Income | -60M | -61M | -42M | -62M | -62M |
| Net Income | -58M | -60M | -42M | -63M | -63M |
| EBITDA | -60M | -61M | -42M | -62M | -62M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 130.97 | 5.5 |
| Next quarter | N/A | 3 | 2.5 |
| Current year | 2374.45 | 31.2 | 10 |
| Next year | -18.53 | -66.18 | 1.0 |
| Weighted average score | 4.8 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -46.01 | -33.32 | -28.09 | 3.3 |
| Y/Y | 999 | -40.81 | 15.79 | -98.09 | 5.3 |
| 3y average | 273.01 | -7.87 | 13.05 | -7.03 | 5.0 |
| 5y average | 350.27 | -9.12 | 8.78 | -9.06 | 4.5 |
| Weighted average score | 4.5 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $73.0M significantly exceed its total debt $58.4M, ensuring strong financial flexibility
Total current assets $111.9M exceed Total current liabilities $14.0M, highlighting excellent liquidity
Debt-to-equity ratio (1.4) is near the industry average, reflecting balanced leverage
Interest coverage ratio (-17.6x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$12.6M limits the company's ability to reinvest or pay down debt